Across TCGA pan-cancer cohorts, KRTAP17-1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRTAP17-1 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher KRTAP17-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP17-1 expression acts as an unfavorable survival marker.
SARC, LGG, and COAD are the cancer types where KRTAP17-1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.